A Randomized, Open-Label, Cross-Over, Study to Evaluate the Inhibitory Effect of Clopidogrel, EC Aspirin 81 mg and EC Omeprazole 40 mg All Dosed Concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers.

Trial Profile

A Randomized, Open-Label, Cross-Over, Study to Evaluate the Inhibitory Effect of Clopidogrel, EC Aspirin 81 mg and EC Omeprazole 40 mg All Dosed Concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2013

At a glance

  • Drugs Aspirin/omeprazole (Primary) ; Aspirin; Clopidogrel; Omeprazole
  • Indications Cardiovascular disorders; Embolism and thrombosis; NSAID-induced gastrointestinal damage
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms Co-Rx
  • Most Recent Events

    • 29 Aug 2012 Results have been presented at the European Society of Cardiologists 2012 Congress according to a POZEN media release.
    • 16 Mar 2012 Official Title amended as reported by ClinicalTrials.gov.
    • 16 Mar 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01557335).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top